IEPA.d108.s251
440
Long-term changes in gastrin, cholecystokinin and insulin in response to oxytocin treatment
IEPA.d108.s251.e0
992
insulin
IEPA.d108.s251.e1
993
oxytocin
IEPA.d108.s251.i0
IEPA.d108.s251.e0
IEPA.d108.s251.e1
PPI
IEPA.d108.s252
441
The present study was designed to investigate how repeated injections of oxytocin influence plasma levels of vagally controlled hormones such as gastrin, cholecystokinin (CCK), insulin and somatostatin, as well as of endogenous oxytocin and glucose
IEPA.d108.s252.e0
994
oxytocin
IEPA.d108.s252.e1
995
insulin
IEPA.d108.s252.e2
996
oxytocin
IEPA.d108.s252.i0
IEPA.d108.s252.e0
IEPA.d108.s252.e1
PPI
IEPA.d108.s253
442
In addition, both insulin and CCK levels were decreased in response to the oxytocin treatment when measured 3 and 10 days after the last injection (ANOVA; insulin p < 0.01, CCK p < 0.05)
IEPA.d108.s253.e0
997
insulin
IEPA.d108.s253.e1
998
oxytocin
IEPA.d108.s253.e2
999
insulin
IEPA.d108.s253.i0
IEPA.d108.s253.e0
IEPA.d108.s253.e1
PPI
IEPA.d108.s254
443
When the alpha2-adrenoreceptor agonist clonidine (2.5 microgram/kg intracerebroventricularly) was administered 3 days after the 5-day treatment period with oxytocin or saline, plasma levels of insulin and CCK increased significantly (p < 0.05) in the oxytocin-treated rats, when compared to saline-treated controls receiving clonidine only
IEPA.d108.s254.e0
1000
oxytocin
IEPA.d108.s254.e1
1001
insulin
IEPA.d108.s254.e2
1002
oxytocin
IEPA.d108.s255
444
In conclusion, these results show that oxytocin induces long-lasting changes in plasma levels of gastrin, CCK and insulin, without affecting somatostatin or glucose levels
IEPA.d108.s255.e0
1003
oxytocin
IEPA.d108.s255.e1
1004
insulin
IEPA.d108.s255.i0
IEPA.d108.s255.e0
IEPA.d108.s255.e1
PPI